Alamar Biosciences, Inc.

Alamar Biosciences, Inc. develops and commercializes proteomics and immunoassay instruments, consumables, and related services for life-science research. Its core platform includes the ARGO HT instrument, NULISA assay consumables, and TAP services, with sales primarily in North America, Europe, and Asia through direct and distribution channels.

— Alamar Biosciences, Inc.
%
Instruments45% Benchtop analytical instruments used for proteomics and immunoassay workflows.
Consumables40% Assay consumables and kits used on installed instruments for recurring testing.
Services15% TAP Services, analytical testing, and maintenance/repair contracts.

Customers are primarily academic and research institutions, biopharmaceutical companies, contract research...

  • Academic and research institutionsprimary

    Universities and research centers buy instruments, consumables, and TAP Services for basic and translational research.

  • Biopharmaceutical companiesprimary

    Drug developers use the platform for biomarker discovery, assay validation, and preclinical research.

  • Contract research organizationssecondary

    CROs purchase services and systems to support outsourced analytical programs for pharma and biotech clients.

  • Service laboratoriessecondary

    Labs buy instruments and consumables to offer testing and analytical services to third parties.

  • Distributorssecondary

    Channel partners resell products in selected international markets where direct coverage is limited.

Alamar sells primarily through direct channels in North America, Europe, and China, with additional distribution...

  • North America is the main commercial base and largest revenue region
  • Europe is a major market served through direct sales and distributors
  • China is a named direct-sales market and an important growth geography
  • APAC sales include Australia, Japan, Singapore, and South Korea
  • International expansion increases currency and supply-chain exposure

The company is expanding its installed base by broadening sales coverage, adding new instruments, and improving the...

01
Expand the installed baseshort-term

A larger installed base increases recurring consumables demand and service revenue.

02
Broaden product capabilitiesmedium-term

More applications and improved performance support adoption and customer retention.

03
Enter translational and diagnostic marketslong-term

Future regulated products could expand the addressable market beyond RUO research use.

The business depends on a small number of specialized suppliers and on customer funding cycles, so supply interruptions...

high

Single-source supply dependence

A majority of key antibodies and some instrument components come from single suppliers, creating shortage risk.

Scope
NULISA assay antibodies and instrument/consumable components
Materiality
high
high

Regulatory transition risk

If products are viewed as clinical diagnostics, marketing authorization could be required before sale.

Scope
ARGO HT/DX and any future diagnostic applications
Materiality
high
medium

Customer funding and seasonality

Many customers rely on government grants and year-end budgets, which can shift purchase timing.

Scope
Instrument and consumables orders
Materiality
high
medium

Foreign exchange volatility

A portion of revenue is denominated in euros and other foreign currencies, affecting reported results.

Scope
Europe and other international markets
Materiality
medium
medium

Trade and logistics disruption

Tariffs, shipping delays, and labor shortages can disrupt supply and customer delivery.

Scope
Global manufacturing and distribution network
Materiality
medium
Revenue recognition by product type
Can create quarter-to-quarter volatility in reported sales
Seasonality
Makes first-quarter and fourth-quarter results less comparable
Inventory reserves and warranty obligations
Affects gross margin and cost of revenue
Convertible note fair value
Can add volatility below operating income
Foreign currency exposure
Can affect revenue, expenses, and other income/expense

: 11/08/2026